The Optivus Advantage

Based on Optivus' history of safety, patient throughput, reliability, project management, training and state-of-the-art technology, Optivus is clearly the most desireable choice for institutions considering proton therapy.


Our unique clinical experience allows us to apply nearly 2 decades of knowledge about the daily activities of patients, therapists and field service team into the design of a new facility – everything from software, to patient positioning, to floor plan design.


Optivus' proprietary technologies have established more impressive benchmarks than any other proton facility in the world.


Accomplishments:


  • Treat 5 times more types of cancer
  • 10 more years of proprietary knowledge, experience and expertise than our competition
  • First to receive FDA clearance for Proton Beam Therapy
  • Obtained coverage by most health insurance carriers, including Medicare
  • Upgrade, service and maintain the James M. Slater Proton Therapy Research Center (JMSPTRC) facility for over 18 years
  • Treatment of nearly 13,000 patients
  • Designed and engineered the sixth-generation FDA certified system – the Conforma 3000 – capable of treating 3,000 patients per year
  • Built and maintained the only proton therapy facility capable of treating 175 patients per day
  • Maintained a perfect safety record for nearly a half-million individual patient treatments
  • 98% system reliability for over 10 years
  • 22 U.S. patents (50-plus worldwide)
  • 18 years of clinical outcome data
  • Received $75 million of Government R/D grants for the JMSPTRC
"I am a senior academic Pathologist who taught medical school for over 32 years and conducted tumor biology research for over 40 years. When I was diagnosed with early stage prostate cancer (T1c), I chose proton beam therapy because the treatment had a very low side effect profile with minimal to no incotinence and a high chance of maintaining sexual potency. The treatments were painless and, except for mild swelling, were unremarkable."

H. Terry Wepsic, M.D.